339 New COVID-19 Cases Since Thursday at Noon

    & 4 Deaths Reported

50,563 Total Positive Cases & 1,154 Total Deaths

MOHAVE COUNTY, AZ (February 14, 2022) — The Mohave County Health Department (MCDPH) Nursing staff has been notified of 339 new confirmed COVID-19 cases reported since Thursday at noon. There are also 4 newly reported deaths.

Of the four newly reported deaths, one is a 20-29 person from the Bullhead City service area, a previously reported confirmed positive case.

One death is an 80-89 person from the Kingman service area, a previously reported confirmed positive case.

One death is an 80-89 individual from the Lake Havasu City area. That person is also one of today’s new confirmed positive cases also.

The final death reported is from an Unknown area of the county, a 70-79 person and that individual is also one of today’s new confirmed positive cases.

ALL 339 of the new confirmed positive cases remain under investigation.

Of the 339 new confirmed cases, there are 145 confirmed cases in the Bullhead City service area. There are 108 new confirmed cases in the Kingman service area. There are 74 new confirmed cases in the Lake Havasu City service area. There are 5 new confirmed cases in the North County service area.  There are 7 new confirmed cases in an Unknown area of the county.

Of the 145 new confirmed cases in the Bullhead City area, 12 are 0-10; 14 are 11-19; 14 are 20-29; 17 are 30-39; 20 are 40-49; 15 are 50-59; 28 are 60-69; 18 are 70-79; 5 are 80-89; 2 are 90+.

Of the 108 new confirmed cases in the Kingman area, 10 are 0-10; 9 are 11-19; 20 are 20-29; 13 are 30-39; 10 are 40-49; 14 are 50-59; 17 are 60-69; 12 are 70-79; 3 are 80-89.

Of the 74 new confirmed cases in the Lake Havasu City area, 1 is 0-10; 2 are 11-19; 4 are 20-29; 9 are 30-39; 6 are 40-49; 13 are 50-59; 17 are 60-69; 13 are 70-79; 6 are 80-89; 3 are 90+.

Of the 5 new confirmed cases in the North County area, 3 are 20-29l 1 is 50-59; 1 is 70-79.

Of the 7 new confirmed cases in an Unknown/Undermined area of the county, 2 are 0-10; 3 are 60-69; 1 is 70-79; 1 is 80-89.

TOTAL RECOVERED THUS FAR: 36,226

AVERAGE AGE OF CASES SINCE CASE #1: 44.7

AVERAGE AGE OF DEATHS SINCE FIRST DEATH: 72.0

In the United States, CDC uses genomic surveillance to track variants of SARS-CoV-2, the virus that causes COVID-19, to more quickly identify and act upon these findings to best protect the public’s health. CDC reports that if a variant is circulating at 0.1% frequency, there is a 99% chance it will be detected in CDC’s national genomic surveillance.

CDC scientists will continue working with partners to gather data and virus samples that can be studied to answer essential questions and inform public health practice regarding the Omicron variant as it spreads in the U.S. and other parts of the world.

The Omicron variant likely will spread more easily than the original SARS-CoV-2 virus. CDC expects that anyone with Omicron infection can spread the virus to others, even if they are vaccinated or don’t have symptoms. More data is needed to know if Omicron infections, reinfections, and breakthrough infections in fully vaccinated people cause more severe illness or death than infection with other variants. The CDC says COVID-19 vaccines remain the best public health measure to protect people from severe illness, slow transmission of the virus, and reduce the likelihood of new variants emerging.

Protect yourself and others

• Get Vaccinated
• Wear a mask in areas of substantial or high transmission
• Stay 6 feet away from others
• Avoid crowds and poorly ventilated spaces
• Wash your hands often
• Clean and disinfect high touch surfaces
• Cover coughs and sneezes
• Test to prevent the spread to others
• Monitor your health daily – Be alert for symptoms

 For more detailed information, please visit https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html

Treatment Options

ADHS has launched a new website for treatments in Arizona to complement the current monoclonal antibodies website.

ADHS – Everyone – Monoclonal Antibodies (mAbs) (azdhs.gov)

ADHS – Everyone – Find Treatment (azdhs.gov)

ADHS – Everyone – Antivirals (azdhs.gov)

While vaccines provide the best protection from COVID-19, treatment options such as Monoclonal Antibody therapy can shorten the duration of symptoms and reduce the risk of severe illness and hospitalization.

Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection — in this case, the virus that causes COVID-19 — and are given to patients directly with an infusion or a shot. Your body naturally makes antibodies to fight infection. However, your body may not have antibodies designed to recognize a new virus-like the virus that causes COVID-19. That’s why mAb treatment may help patients at high risk for severe symptoms or hospitalization.

The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to allow the use of monoclonal antibody therapies for the treatment of mild to moderate COVID19 in certain high-risk patients. Some people who have been exposed to COVID-19 may qualify for treatment even before testing positive for COVID-19. This treatment is not a substitute for vaccination against COVID-19.

General eligibility information is below.

• Individuals who have tested positive for COVID-19 and are within ten days of onset
• Unvaccinated individuals who have had close contact with a COVID positive person
• Vaccinated individuals who are immunocompromised and have had close contact with a COVID-positive person
• Each facility has its standards for administering Monoclonal Antibody Therapy. Please visit their respective websites or call the number provided below for more information.

 Kingman Regional Medical Center (KRMC)

Website:

Seeking Medical Care For Covid-19 | KRMC | Kingman Regional Medical Center (azkrmc.com)

Phone Number: 928-681-8699

Western Arizona Regional Medical Center (WARMC)

Website: https://www.warmc.com/covid-19

Phone number: 928-763- 2273

Havasu Urgent Care (aka Havasu Primary Care and Pediatrics)

Phone number: 928-505-1030

Veklury® (Remdesivir) (FDA approved)

Veklury® (Remdesivir) works by slowing the replication of the COVID-19 virus, thereby reducing the amount of virus circulating in the body. Veklury® (Remdesivir) is approved for hospitalized patients age 12 years and older who weigh at least 88 pounds, with more severe COVID-19 disease. Your hospital care team will decide if you are eligible to receive this treatment.

Additional COVID-19 Questions?, Please Call 928-753-8665

This brought to you by